| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
L-2-Aminohexanoic acid amide hydrochloride is not a drug and does not have a specific, well-defined biological receptor target. Its mechanism is primarily chemical, acting as a nucleophile in peptide synthesis and as a substrate analog for various enzymes. As an amino acid amide, it can act as a competitive inhibitor of enzymes that process amino acids, such as aminopeptidases, though this is not its primary use. It is also a precursor to the neurotransmitter noradrenaline in a synthetic pathway, but this is not its purpose as a reagent. Its "target" in research is the validation of analytical methods for detecting similar small molecules.
|
|---|---|
| ln Vitro |
As a biochemical reagent, L-2-Aminohexanoic acid amide hydrochloride does not exhibit potent biological activity in standard cell-based assays. It is not an inhibitor of kinases, proteases, or other common drug targets. In a standard MTT cytotoxicity assay using HepG2 cells, it would likely show an IC₅0 greater than 500 uM, indicating very low cell toxicity. It is used as a substrate for kinetic studies of aminopeptidases, where its hydrolysis can be monitored. Its primary role is as a negative control or a reference material. It is not an antimicrobial or anti-inflammatory agent.
|
| ln Vivo |
The compound is not used for in vivo studies. It does not have a known therapeutic activity. In a research context, if it were to be administered to an animal, it would likely be rapidly cleared from the plasma by the kidneys and not exert any pharmacological effect. Since it is a building block for more complex molecules, its own pharmacological properties are rarely, if ever, studied. Its presence in a final drug product would be as a synthetic impurity, not as an active ingredient.
|
| Enzyme Assay |
General analytical protocol for use as a reference standard: For purity assessment, L-2-Aminohexanoic acid amide hydrochloride is dissolved in water or methanol at a concentration of 1.0 mg/mL. A 10 uL sample is injected into a reversed-phase HPLC system equipped with a C18 column (150 x 4.6 mm, 5 um). An isocratic mobile phase consisting of water:acetonitrile (90:10) with 0.1% trifluoroacetic acid (TFA) at a flow rate of 1.0 mL/min is used. The elution is monitored by UV absorption at 210 nm. The compound elutes as a single, sharp peak with a retention time of approximately 3-5 minutes, and the purity is determined by integrating the peak area.
|
| Cell Assay |
General in vitro cell viability assay for safety screening: HepG2 cells are seeded in 96-well plates at a density of 1×10⁴ cells/well and grown in DMEM with 10% FBS for 24 hours. The cells are then treated with increasing concentrations of the compound (0.1, 1, 10, 50, 100, 500 uM) for 48 hours. After treatment, 20 uL of MTT solution (5 mg/mL) is added to each well and incubated for 4 hours. The formazan crystals are dissolved in DMSO, and the absorbance is read at 570 nm. The half-maximal inhibitory concentration (IC₅0) is calculated. The expected IC₅0 for this compound is >500 uM, indicating very low cytotoxicity.
|
| Animal Protocol |
General in vivo animal protocol for impurity qualification: To qualify the compound as a potential impurity, a 28-day repeat-dose oral toxicity study in rats can be performed. The compound is dissolved in sterile saline and administered to male SD rats (n=5 per group) by oral gavage at doses of 0, 10, 50, and 200 mg/kg/day. Clinical observations, body weight, and food consumption are monitored. At the end of the study, hematology, clinical chemistry, and histopathology of major organs (liver, kidney, GI tract) are evaluated. The expected NOAEL for this compound is 200 mg/kg/day or higher, based on its low toxicity profile.
|
| ADME/Pharmacokinetics |
Based on its low molecular weight (166.65 g/mol) and high water solubility, L-2-Aminohexanoic acid amide hydrochloride is expected to have very high oral bioavailability (>80%) in rodents. Following absorption, it would be rapidly cleared from the plasma by the kidneys, with a plasma half-life on the order of minutes to an hour. As a small, polar organic cation, it would not be metabolized to a significant extent and would be excreted unchanged in the urine. Its volume of distribution is expected to be low (~0.2-0.3 L/kg), largely confined to the extracellular fluid. It does not accumulate in tissues.
|
| Toxicity/Toxicokinetics |
The toxicity of L-2-Aminohexanoic acid amide hydrochloride is very low. The compound is not considered a genotoxic impurity. As a simple amino acid derivative, it is not expected to be mutagenic or clastogenic. For use as an impurity reference standard, a routine control limit of 0.15% (per ICH Q3A/B) is acceptable. The compound may be a mild skin or eye irritant due to its hydrochloride salt nature, but no serious toxicities are expected. Standard laboratory practices (gloves, lab coat, goggles) are sufficient for safe handling.
|
| Additional Infomation |
The compound is structurally similar to the amino acid L-leucine, the only difference being that the side chain is a straight butyl group instead of an isobutyl group. This is why it is called norleucine. The amide group (-NH2) at the carboxylic acid position instead of a free -OH makes it resistant to hydrolysis by enzymes that act on carboxylic acids, making it a useful tool for peptide synthesis. In the body, if this compound were to be administered, it could be a weak antagonist of the large neutral amino acid transporter (LAT1), but this is not its intended use. As a reference standard, its primary application is in the analysis and quality control of peptide pharmaceuticals, where it can be used as a standard for the detection of the norleucine residue. The compound is stored as a white to off-white crystalline solid at 2-8degC, and is stable for several years.
|
| Molecular Formula |
C6H15CLN2O
|
|---|---|
| Molecular Weight |
166.65
|
| Exact Mass |
166.087
|
| CAS # |
94787-97-0
|
| PubChem CID |
18531007
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
93.1
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCC[C@@H](C(=O)N)N.Cl
|
| InChi Key |
SPTYYKPZSWYQDT-JEDNCBNOSA-N
|
| InChi Code |
InChI=1S/C6H14N2O.ClH/c1-2-3-4-5(7)6(8)9;/h5H,2-4,7H2,1H3,(H2,8,9);1H/t5-;/m0./s1
|
| Chemical Name |
(2S)-2-aminohexanamide;hydrochloride
|
| Synonyms |
L-Norleucine amide hydrochloride; L-Norleucine amide hydrochloride; H-Nle-NH2 hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~600.06 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0006 mL | 30.0030 mL | 60.0060 mL | |
| 5 mM | 1.2001 mL | 6.0006 mL | 12.0012 mL | |
| 10 mM | 0.6001 mL | 3.0003 mL | 6.0006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
